Drug
Lorcaserin clinical trials
Also written Belviq and APD356.
- studies test it
- 47
- open now
- 0
- in phase 3
- 8
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
47 studies that test it; most in 2008 (6)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 6 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 5 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 21
- Phase 2
- 15
- Phase 3
- 8
- Phase 4
- 7
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 26
Eisai Inc. (17) · New York State Psychiatric Institute (4) · Mayo Clinic (3) · Virginia Commonwealth University (2) · National Institute on Drug Abuse (NIDA) (2) · Duke University (2) · The Mind Research Network (2) · Beth Israel Deaconess Medical Center (1)
Often tested with
Tested in the same studies.
Phentermine (1) · Nicotine Patch (1) · Varenicline (1) · Cocaine (1) · Metformin (1) · Ziprasidone (1)
Studies
Open first, then newest update. How each study uses lorcaserin is read from its arms, and is right about nine times in ten.
Testing it · 47
- Lorcaserin in Obesity: Identification of CNS Targets Using fMRIActive, not recruitingPhase 4Beth Israel Deaconess Medical CenterNCT02400359Written as Lorcaserin HCl
- Rebalancing the Serotonergic System in Cocaine DependenceWithdrawnPhase 1Mclean HospitalNCT03266939Written as Lorcaserin
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeTerminatedPhase 3Eisai Inc.NCT04572243Written as Lorcaserin
- Predictors of Lorcaserin-Induced Weight LossTerminatedPhase 4Columbia UniversityNCT03353220Written as Belviq
- Treatment With Lorcaserin for Cocaine Use: The TLC StudyTerminatedPhase 2Glenn-Milo SantosNCT03192995Written as lorcaserin
- Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly SubjectsCompletedPhase 1Eisai Inc.NCT00828581Written as lorcaserin
- Mechanisms of Lorcaserin for Smoking CessationTerminatedPhase 2The Mind Research NetworkNCT04396834Written as Lorcaserin Oral Tablet
- Laboratory Screening of Lorcaserin for Alcohol Use DisorderTerminatedPhase 2The Mind Research NetworkNCT04396847Written as Lorcaserin Oral Tablet
- Effect of Lorcaserin on Cannabis Withdrawal and Self-administrationCompletedPhase 1/2New York State Psychiatric InstituteNCT03253926Written as Lorcaserin
- Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese PatientsTerminatedPhase 3Kanion & Huawe Medicine Co.,LtdNCT03720574Written as Lorcaserin 10 mg BID
- Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 YearsTerminatedPhase 4Eisai Inc.NCT03338296Written as lorcaserin hydrochloride XR
- Addressing Post Cessation Weight GainTerminatedPhase 2/3Mayo ClinicNCT02412631Written as lorcaserin
- MEtformin and Lorcaserin for WeighT Loss in SchizophreniaTerminatedPhase 4University of North Carolina, Chapel HillNCT02796144Written as Lorcaserin
- Lorcaserin for Cannabis Use DisorderTerminatedEarly Phase 1New York State Psychiatric InstituteNCT03637842Written as Lorcaserin
- Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast CancerWithdrawnPhase 1Ohio State University Comprehensive Cancer CenterNCT04205071Written as Lorcaserin
- Drug Interaction and Subjective Effects of Compounds for Opioid Use DisorderCompletedPhase 1Virginia Commonwealth UniversityNCT03143855Written as Lorcaserin
- Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use DisorderCompletedPhase 2/3New York State Psychiatric InstituteNCT03169816Written as Lorcaserin
- Lorcaserin in the Treatment of Cocaine Use DisorderCompletedPhase 2National Institute on Drug Abuse (NIDA)NCT03007394Written as Lorcaserin
- Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use DisorderTerminatedPhase 1Virginia Commonwealth UniversityNCT03143543Written as Group A Lorcaserin (10mg)
- Gene-by-Stress Interactions in Intervention Studies SignificanceTerminatedPhase 1Duke UniversityNCT03011645Written as Lorcaserin
See all 47 studies that test lorcaserin →
Given in every arm · 1 — lorcaserin is usual care beside what is tested
Codes
What other systems call lorcaserin · ClinicalTrials.gg INT004853
- MeSH (NLM) C506658lorcaserinOne source NLM
- UNII (FDA) 637E494O0ZLORCASERINConfirmed FDA, NLM, Wikidata
- RxNorm 1300701Confirmed FDA, Wikidata
- Wikidata Q340139lorcaserinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76102LorcaserinOne source FDA
- DrugBank DB04871One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C506658 | lorcaserin | One source NLM |
| UNII (FDA) | 637E494O0Z | LORCASERIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1300701 | — | Confirmed FDA, Wikidata |
| Wikidata | Q340139 | lorcaserin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76102 | Lorcaserin | One source FDA |
| DrugBank | DB04871 | — | One source Wikidata |
Also registered as lorcaserin hydrochloride anhydrous (UNII 0QJF08GDPE · RxNorm 1300700) and lorcaserin hydrochloride hemihydrate (UNII REV26SR2B4 · RxNorm 1597623).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.